Publicacións (99) Publicacións de Eva Pérez Pampín

2024

  1. Exploring candidate biomarkers for rheumatoid arthritis through cardiovascular and cardiometabolic serum proteome profiling

    Frontiers in Immunology, Vol. 15

  2. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

2023

  1. Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  2. Clinical features and immune mechanisms directly linked to the altered liver function in patients with rheumatoid arthritis

    European Journal of Internal Medicine, Vol. 118, pp. 49-58

  3. Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study

    Rheumatology and Therapy, Vol. 10, Núm. 5, pp. 1319-1333

2022

  1. Antibodies against 4 Atypical Post-Translational Protein Modifications in Patients with Rheumatoid Arthritis

    Diagnostics, Vol. 12, Núm. 2

  2. Association of the serological status of rheumatoid arthritis patients with two circulating protein biomarkers: A useful tool for precision medicine strategies

    Frontiers in Medicine, Vol. 9

  3. Biologics for thyroid eye disease

    Foundational Papers in Oculoplastics (Springer International Publishing), pp. 481-498

  4. ROCK inhibition with Y-27632 reduces joint inflammation and damage in serum-induced arthritis model and decreases in vitro osteoclastogenesis in patients with early arthritis

    Frontiers in Immunology, Vol. 13

  5. Revisión sistemática y metanálisis del efecto del tabaco en la eficacia de los anti-TNF en las enfermedades inflamatorias crónicas inmunomediadas

    Investigación y práctica en salud desde un enfoque integrador (Asociación Universitaria de Educación y Psicología (ASUNIVEP)), pp. 555-564

  6. Validation of screening criteria for spondyloarthritis in patients with inflammatory bowel disease in routine clinical practice

    Digestive and Liver Disease, Vol. 54, Núm. 6, pp. 755-762

2021

  1. HLA–B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti–Carbamylated Protein Antibody–Positive/Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis

    Arthritis and Rheumatology, Vol. 73, Núm. 6, pp. 963-969

  2. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 2, pp. 387-394

  3. Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts

    Frontiers in Immunology, Vol. 12

2020

  1. A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis

    Scientific Reports, Vol. 10, Núm. 1

  2. Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 5, pp. 1101-1108

  3. NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium

    Scientific Reports, Vol. 10, Núm. 1

  4. Publisher Correction: A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis (Scientific Reports, (2020), 10, 1, (3355), 10.1038/s41598-020-60305-x)

    Scientific Reports

  5. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice

    Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 112-119

2019

  1. Correction: Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients (The Pharmacogenomics Journal, (2019), 19, 1, (83-96), 10.1038/s41397-018-0057-x)

    Pharmacogenomics Journal